UGT2B17 pripada porodici UDP-glukuronoziltransferaza (UGT; EC 2.4.1.17), enzima koji katalizuju prenos glukuronske kiseline iz uridin difosfoglukuronske kiseline na različite supstrate, uključujući steroidne hormone.[5] Takođe metabolizuje 3-hidroksikotinin, koji je manje zastupljeni metabolit nikotina.[6]
^„Human PubMed Reference:”. National Center for Biotechnology Information, U.S. National Library of Medicine.
^„Mouse PubMed Reference:”. National Center for Biotechnology Information, U.S. National Library of Medicine.
^Beaulieu M, Levesque E, Hum DW, Belanger A (novembar 1996). „Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids”. J Biol Chem. 271 (37): 22855—62. PMID8798464. doi:10.1074/jbc.271.37.22855.CS1 održavanje: Format datuma (veza)
Chung LW, Coffey DS (1978). „Androgen glucuronide. II. Differences in its formation by human normal and benign hyperplastic prostates.”. Investigative Urology. 15 (5): 385—8. PMID76619.
Moghissi E, Ablan F, Horton R (1984). „Origin of plasma androstanediol glucuronide in men.”. Journal of Clinical Endocrinology & Metabolism. 59 (3): 417—21. PMID6746859. doi:10.1210/jcem-59-3-417.
Beaulieu M, Lévesque E, Tchernof A (1997). „Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme.”. DNA Cell Biol. 16 (10): 1143—54. PMID9364925. doi:10.1089/dna.1997.16.1143.Nepoznati parametar |display-author= ignorisan (pomoć)
Collier AC, Ganley NA, Tingle MD (2002). „UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term.”. Biochem. Pharmacol. 63 (3): 409—19. PMID11853692. doi:10.1016/S0006-2952(01)00890-5.Nepoznati parametar |display-author= ignorisan (pomoć)
Chouinard S, Pelletier G, Bélanger A, Barbier O (2005). „Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium.”. Endocr. Res. 30 (4): 717—25. PMID15666817. S2CID10971899. doi:10.1081/ERC-200044014.
Lazarus P, Zheng Y, Aaron Runkle E (2006). „Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes.”. Pharmacogenet. Genomics. 15 (11): 769—78. PMID16220109. S2CID10171438. doi:10.1097/01.fpc.0000175596.52443.ef.Nepoznati parametar |display-author= ignorisan (pomoć)
Jakobsson J, Ekström L, Inotsume N (2006). „Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism.”. Journal of Clinical Endocrinology & Metabolism. 91 (2): 687—93. PMID16332934. doi:10.1210/jc.2005-1643.Nepoznati parametar |display-author= ignorisan (pomoć)
Park J, Chen L, Ratnashinge L (2006). „Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men.”. Cancer Epidemiol. Biomarkers Prev. 15 (8): 1473—8. PMID16896035. doi:10.1158/1055-9965.EPI-06-0141.Nepoznati parametar |display-author= ignorisan (pomoć)
Gallagher CJ, Muscat JE, Hicks AN (2007). „The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer.”. Cancer Epidemiol. Biomarkers Prev. 16 (4): 823—8. PMID17416778. doi:10.1158/1055-9965.EPI-06-0823.Nepoznati parametar |display-author= ignorisan (pomoć)
Chouinard S, Barbier O, Bélanger A (2008). „UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells.”. J. Biol. Chem. 282 (46): 33466—74. PMID17848572. doi:10.1074/jbc.M703370200.